| I. COMMENCED TRADING IN OCTOBER | ||||||||
|
|
||||||||
| INITIAL OFFERINGS | ||||||||
|
| ||||||||
| Company | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares | Lead, Other Underwriters | Gross (M) | Net (M) |
| | ||||||||
| There were no initial public offerings in October. | ||||||||
|
| ||||||||
| Total: $0M |
||||||||
| Number of IPOs in October: 0 |
||||||||
| Average value of October IPOs: $0M |
||||||||
| Number of IPOs for 2001: 7 |
||||||||
| Total raised in IPOs in 2001: $207.05M |
||||||||
| Average value of IPOs in 2001: $29.58M |
||||||||
|
| ||||||||
| FOLLOW-ON OFFERINGS |
||||||||
|
| ||||||||
| Company | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares | Lead, Other Underwriters | Gross (M) | Net (M) |
| | ||||||||
| BioMS Medical | 10/23 | 10/23 | 3.3U | C$2.50 | ND | Yorkton Securities Inc. | C$8.25 (US | ND |
|
| ||||||||
| Isis Pharma- | 10/9 | 10/23 | 5.75S | $20 | 52.1 | UBS Warburg LLC; Robertson Stephens Inc.; Needham & Co. Inc.; Fortis Securities Inc. | $115 | $107.8 |
|
| ||||||||
| Sicor Inc. | 10/11 | 10/11 | 10S | $18.50 | 110.7 | Merrill Lynch & Co.; CIBC World Markets Corp.; SG Cowen Securities Corp. | $185 | $175.9 |
|
| ||||||||
| EXERCISED OVERALLOTMENT OPTIONS |
||||||||
|
| ||||||||
| Telik Inc. | 8/20 | 10/18 | 0.6S | $6.50 | 26.9 | Lehman Brothers Inc.; Legg Mason Wood Walker; UBS Warburg LLC; Lazard Freres & Co. LLC; Needham & Co. Inc. | $3.9 | $3.7 |
| Notes: |
||||||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange; CDNX = Canadian Venture Exchange; ND = Not disclosed |
||||||||
| 1 BioMS issued 3.3M units, each consisting of one common share and one-half of a purchase warrant. A full warrant entitles the holder to purchase one common share at C$5.80 each until Oct. 22, 2003. |
||||||||
| 2 Isis' offering includes the full exercise of the underwriters' overallotment option for 750,000 shares. |
||||||||
| 3 Sicor's offering was for 20M shares, 10M sold by the company and 10M sold by stockholder Rakepoll Finance, for total gross proceeds of $370M. Underwriters have an option to purchase 3M shares to cover overallotments. |
||||||||
| 4 Telik's underwriters exercised their overallotment option to purchase an additional 600,000 shares. The offering was completed in September. |
||||||||
|
| ||||||||
| Total: $305.24M |
||||||||
| Number of follow-on offerings in October: 3 |
||||||||
| Average value of October follow-ons: $101.7 |
||||||||
| Number of follow-on offerings in 2001: 31 |
||||||||
| Total raised in follow-ons in 2001: $2,478.71M |
||||||||
| Average value of follow-ons in 2001: $79.6M |
||||||||
|
| ||||||||
| II. FILED AND PENDING |
||||||||
|
| ||||||||
| INITIAL OFFERINGS | ||||||||
|
| ||||||||
| Company | Date Filed | Shares/ Units (M) | Price Range | Shares Out (M) | Lead, Other Underwriters | Value (M) | ||
| | ||||||||
| AgraQuest | 8/3 | N/A | N/A | N/A | Merrill Lynch & Co.; Stephens Inc.; First Union Securities Inc. | $75 | ||
|
| ||||||||
| APBiotech | 10/3/00 | 18.2S | $15-17 | 208.6 | Morgan Stanley Dean Witter (co-lead); Goldman, Sachs & Co. (co-lead); Chase H&Q; Salomon Smith Barney | $291.2 | ||
|
| ||||||||
| BioNumerik | 3/2 | N/A | N/A | N/A | Morgan Stanley Dean Witter; UBS Warburg LLC; SG Cowen Securities Corp. | $50 | ||
|
| ||||||||
| CombiMatrix | 11/22 | N/A | N/A | N/A | Salomon Smith Barney (co-lead); JP Morgan & Co. (co-lead) | $100 | ||
|
| ||||||||
| diaDexus Inc. | 11/20 | 7S | $12-14 | 31.1 | Lehman Brothers Inc.; CIBC World Markets Corp.; Robertson Stephens Inc.; Fidelity Capital Markets | $91 | ||
|
| ||||||||
| Northwest | 8/13 | 3.5S | $9-$11 | 16.5 | C.E. Unterberg, Towbin | $35 | ||
|
| ||||||||
| Ribapharm | 5/15 | 18S | $13-15 | N/A | UBS Warburg LLC; CIBC World Markets Corp. | $252 | ||
|
| ||||||||
| Xcyte | 12/22 | N/A | N/A | N/A | SG Cowen Securities Corp. (co-lead); U.S. Bancorp Piper Jaffray (co-lead); Dain Rauscher Inc.; First Security Van Kasper Inc. | $86.2 | ||
|
| ||||||||
| ZymoGenetics | 9/10 | N/A | N/A | N/A | Lehman Brothers Inc. (co-lead); Merrill Lynch & Co. (co-lead); Bear, Stearns & Co. Inc.; Pacific Growth Equities Inc. | $180 | ||
|
| ||||||||
| FOLLOW-ON OFFERINGS | ||||||||
|
| ||||||||
| Ariad Pharma- | 6/22 | 4.5S | $4.79 | 34.6 | N/A | $21.6 | ||
|
| ||||||||
| Cell Pathways | 2/7 | N/A | N/A | N/A | N/A | $25 | ||
|
| ||||||||
| Cerus Corp. | 8/13 | N/A | N/A | 15.7 | N/A | $300 | ||
|
| ||||||||
| CollaGenex | 10/26 | 0.965S | $8.01 | N/A | N/A | $7.7 | ||
|
| ||||||||
| Cytogen Corp. | 10/26 | 10S | $2.50 | 78.9 | N/A | $25 | ||
|
| ||||||||
| Exelixis Inc. | 7/30 | N/A | N/A | 49.2 | N/A | $150 | ||
|
| ||||||||
| Genaissance | 10/18 | N/A | N/A | 22.8 | N/A | $35 | ||
|
| ||||||||
| ICOS Corp. | 6/26 | N/A | N/A | 53 | N/A | $300 | ||
|
| ||||||||
| InSite | 2/2 | N/A | N/A | N/A | Ladenburg Thalmann & Co. (placement agent) | $40 | ||
|
| ||||||||
| Labopharm | 10/29 | 5.2S | C$6.75 | N/A | Research Capital Corp.; CIBC World Markets Corp.; National Bank Financial Inc.; TC Securities Inc. | C$35.1 (US | ||
|
| ||||||||
| Matrix Pharm- | 5/25 | N/A | N/A | 26 | N/A | $30 | ||
|
| ||||||||
| Microcide | 2/12 | N/A | N/A | N/A | N/A | $35 | ||
|
| ||||||||
| Neo- | 1/3 | N/A | N/A | 21.9 | N/A | $50 | ||
|
| ||||||||
| Tularik Inc. | 8/14 | N/A | N/A | 49.2 | N/A | $250 | ||
|
| ||||||||
| Valentis Inc. | 9/27 | N/A | N/A | 29.9 | N/A | $45 | ||
|
| ||||||||
| ViroPharma | 7/3 | N/A | N/A | 18.7 | N/A | $300 | ||
|
| ||||||||
| Vysis Inc. | 8/8 | 1S | $25.96 | 11.2 | UBS Warburg LLC; First Union Securities Inc.; Pacific Growth Equities Inc. | $26 | ||
|
| ||||||||
| III. WITHDRAWN AND POSTPONED | ||||||||
|
| ||||||||
| INITIAL OFFERINGS | ||||||||
|
| ||||||||
| Company | Date Filed/ Date Pulled | Shares/ Units (M) | Price Range | Shares Out (M) | Lead, Other Underwriters | Value (M) | ||
| | ||||||||
| Cellomics | 3/7/00 | 6S | $8-$10 | 24.2 | Prudential Vector Healthcare; ING Barings LLC; Dain Rauscher Wessels | $54 | ||
|
| ||||||||
| Notes: | ||||||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||||
| * Stock symbols for companies seeking to complete IPOs are proposed. | ||||||||
| N/A = Not available, applicable or reported. | ||||||||
| TSE = Toronto Stock Exchange | ||||||||
| 1 AgraQuest filed a registration statement with the SEC to raise $75M in an IPO. | ||||||||
| 2 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range. | ||||||||
| 3 BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed. | ||||||||
| 4 CombiMatrix did not disclose any further details. | ||||||||
| 5 diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares. | ||||||||
| 6 Northwest filed for an IPO expected to raise $48.3M in August. It amended the filing in October to raise $35M. The underwriter has an overallotment option for an additional 525,000 shares. | ||||||||
| 7 Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares. | ||||||||
| 8 Xcyte did not disclose any further details. | ||||||||
| 9 ZymoGenetics filed to raise $180M in an IPO. | ||||||||
| 10 Ariad's offering value is based on the proposed maximum offering share price of $4.79. | ||||||||
| 11 Cell Pathways filed a shelf registration for the sale of $25M in common stock. | ||||||||
| 12 Cerus filed to sell up to $300M of common stock and debt in a shelf offering. | ||||||||
| 13 The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01. | ||||||||
| 14 Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration. | ||||||||
| 15 Exelixis filed a shelf registration to sell up to $150M in common stock. | ||||||||
| 16 Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M. | ||||||||
| 17 ICOS filed a shelf registration statement for up to $300M. | ||||||||
| 18 InSite filed a shelf registration to sell $40M in stock | ||||||||
| 19 Labopharm's underwriters have an option to purchase an additional 780,000 shares to cover overallotments. | ||||||||
| 20 Matrix filed a shelf registration covering up to $30M in securities. | ||||||||
| 21 Microcide filed a shelf registration for the sale of up to $35M in securities. (Microcide is now Essential Therapeutics Inc. , formed through its merger with The Althexis Company Inc.) | ||||||||
| 22 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. The company amended its prospectus April 19. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. | ||||||||
| 23 Tularik filed to sell up to $250M in common stock and debt securities. | ||||||||
| 24 Valentis filed to sell up to $45M worth of equity warrants, preferred and common stock through a shelf registration statement. | ||||||||
| 25 ViroPharma filed a universal shelf registration for $300M in mixed securities. | ||||||||
| 26 Vysis registered to sell 4M shares, 3M of which will be sold by shareholder BP plc. The value of the offering, $26M, is based on the closing stock price of $25.96 on Aug. 7. The underwriters have an overallotment option for 600,000 shares. (Vysis is now being purchased by Abbott Laboratories.) | ||||||||
| 27 Cellomics postponed its initial public offering proposed in December 2000. It withdrew it in October, citing market conditions. | ||||||||
